2024-04-16 08:44:59 ET
DENVER, Colo., Apr 16, 2024 ( 247marketnews.com )- Palisade Bio, Inc. (Nasdaq: PALI ) stated that it successfully completed its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC, demonstrating that PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with UC.
“The results from this study underscore our confidence in PALI-2108 as a targeted treatment for moderate-to-severe UC,” stated Dr. Mitch Jones, Palisade Bio’s CMO. “The successful bioactivation of prodrug PALI-2108 into its active PDE4 inhibitor form at consistently high conversion rates over a 24-hour period in stool samples highlights its promise as an innovative therapeutic approach for managing UC.”
The post Palisade Bio Successfully Demonstrates PALI-2108 Bioactivation appeared first on 24/7 MarketNews .
For further details see:
Palisade Bio Successfully Demonstrates PALI-2108 Bioactivation